Clinical Trials
14 trialsNCT05797168 2026-06-03
FONTANA
AstraZeneca
Phase 1/2 Recruiting
NCT05566223 2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2 Withdrawn
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT04339218 2026-01-30
CRYOMUNE
Institut Bergonié
Phase 3 Recruiting
NCT05887492 2025-11-18
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03184571 2025-09-25
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
BerGenBio ASA
Phase 2 Completed
NCT04533451 2025-06-13
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT05266846 2024-05-30
BEYOND
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT04027946 2024-04-16
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04682431 2024-03-22
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT04691375 2024-03-22
A Study of PY314 in Subjects With Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT05081674 2023-10-11
BLISS
Hospital Israelita Albert Einstein
Phase 2 Completed
NCT04452214 2023-07-14
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
Phase 1 Completed
NCT03254004 2020-12-14
Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm
Samsung Medical Center
Phase 2 Unknown